Gosset Sequel Med Tech General Information
Sequel Med Tech has developed and commercialized the twiist Automated Insulin Delivery system, an FDA-cleared device that integrates advanced insulin pump technology with real-time continuous glucose monitoring. The system leverages the Tidepool algorithm for automated insulin dosing and offers compatibility with both implantable long-duration CGMs from Senseonics and widely used sensors from Abbott. Clinical evidence supports meaningful improvements in glycemic control for people living with type 1 diabetes. The company emphasizes accessibility through pharmacy channels to increase adoption among patients who require insulin therapy but are not currently using AID systems.
Contact Information
United States
Drug Pipeline
Key Partnerships
Senseonics Holdings Inc. – integration of Eversense long-duration CGM sensor into AID platform, Abbott – compatibility of twiist AID system with FreeStyle Libre CGM sensor
Sequel Med Tech Funding
No funding data available